Aurinia Pharmaceuticals stock (CA05156H1070): Announces $6.955 Cash Acquisition of Kezar Life Sciences

Aurinia Pharmaceuticals, a biopharmaceutical company focused on autoimmune and kidney diseases, announced on March 30, 2026, its intent to acquire Kezar Life Sciences, Inc. for approximately $6.955 in cash per share. This deal, detailed in a StockTitan filing as of March 30, 2026, aims to bolster Aurinia's clinical-stage assets in immunology. The stock rose 1.72% to $15.99 on Nasdaq, per TradingKey data as of May 13, 2026.

As of: 13.05.2026

By the editorial team – specialized in equity coverage.

Aurinia Pharmaceuticals: core business model

Aurinia Pharmaceuticals develops therapies for rare diseases, particularly lupus nephritis and other immune-mediated conditions. Its lead product, Lupkynis (voclosporin), is an FDA-approved calcineurin inhibitor for lupus nephritis treatment, generating key revenue since its 2021 launch. The company reported Lupkynis net product sales of $123.5 million for full-year 2024, published in Q4 earnings on March 12, 2025, via its investor site.

Listed on Nasdaq under AUPH and Toronto Stock Exchange, Aurinia targets US investors through its strong presence in the American biotech market, where kidney disease therapies address a significant unmet need.

Main revenue and product drivers for Aurinia Pharmaceuticals

Lupkynis remains the primary revenue driver, with Q1 2025 sales reaching $31.2 million, up 10% year-over-year, as per the company's May 2025 earnings release on ir.auriniapharma.com as of May 13, 2026. Pipeline candidates include AUR200 and AUR300, advancing in clinical trials for immune disorders.

Geographic revenue is heavily US-focused, with over 70% from North America, making it relevant for US retail investors tracking biotech growth stocks.

Industry trends and competitive position

The lupus nephritis market is projected to grow to $1.2 billion by 2030, per EvaluatePharma estimates published in 2025. Aurinia competes with Roche's Actemra and GSK's Benlysta, but Lupkynis offers a differentiated oral option, capturing market share in the US.

Why Aurinia Pharmaceuticals matters for US investors

Aurinia's Nasdaq listing and FDA-approved product provide direct exposure to US biotech innovation. With $200+ million in cash reserves as of Q1 2025 filings, it funds pipeline expansion amid rising demand for rare disease treatments in the American healthcare system.

Conclusion

The Kezar acquisition positions Aurinia Pharmaceuticals to strengthen its immunology portfolio, complementing Lupkynis growth. Recent share price momentum reflects market optimism, though integration risks remain. US investors may monitor upcoming earnings for deal progress updates.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.